Adherence in pediatric ALL

Observational study of 6 mercaptopurine in pediatric acute lymphoblastic leukemia - Adherence of 6-MP in pediatric ALL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045155

Enrollment

Registered

2021-08-14

Start date

2021-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients under 20 years old on diagnosis who will initiate 6-MP as maintenance therapy for ALL. 2. Patients who provide written informed consents.

Exclusion criteria

Exclusion criteria: 1. Patients with relapsed ALL. 2. Patients who can not provide informed consent. 3. Other reasons.

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this study is the adherence of 6-MP.	—

Secondary

Measure	Time frame
1. the proportion of the patients with adherence higher than 90%. 2. Cluster analysis by drawing scatter plots of 6-MMP and 6-TGN concentrations. 3. Chronological changes of adherence.	—

Countries

Japan

Contacts

Public ContactReo Tanoshima

Yokohama City University Hospital Pediatrics

reotano@yokohama-cu.ac.jp045-787-2800

Outcome results